You are here

  • Home
  • Archive
  • Volume 73, Issue 5
  • Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Poddubnyy D, Hermann KA, Callhoff J, et al
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Annals of the Rheumatic Diseases 2014;73:817-823.